Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups

World Journal of Urology

Volumn 33, Issue 12, 2015, Pages 1951-1957

  Ding, Weihong ^a   Tong, Shijun ^a   Gou, Yuancheng ^a   Sun, Chuanyu ^a   Wang, Hong ^a   Chen, Zhongqing ^a   Tan, Jun ^b   Xu, Ke ^a   Xia, Guowei ^a   Ding, Qiang ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

EORTC; HER 2; Immunohistochemistry; Non muscle invasive bladder cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; AGED; BLADDER TUMOR; CARCINOMA; COHORT ANALYSIS; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84947614702     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1557-9     Document Type: Article

References (31)

1. Parkin MD, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
2. Babjuk M et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008
3. Kurth KH et al (1995) Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31A:1840–1846
4. Allard P et al (1998) The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 81:692–698
5. Soloway MS (2007) It is time to abandon the “superficial” in bladder cancer. Eur Urol 52:1564–1565
6. Bryan RT, Wallace DM (2002) ”Superficial” bladder cancer—time to uncouple pT1 tumours from pTa tumours. BJU Int 90:846–852
7. Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477
8. Ding Weihong et al (2014) Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer? Cancer Epidemiol 38:157–161
9. Sylvester RichardJ (2011) How well can you actually predict which non-muscle-invasive bladder cancer patients will progress? Eur Urol 60:431–434
10. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976
11. Olayioye MA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159–3167
12. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl. 2):1–13
13. Sato K et al (1992) An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70:2493–2498
14. Chow NH et al (2001) Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957–1962
15. Gandour-Edwards R et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009–1015
16. Latif Z et al (2003) HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89:1305–1309
17. Latif Z et al (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40:56–63
18. Coogan CL et al (2004) HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786–790
19. Kruger S et al (2005) Protein expression and gene copy number analysis of topoisomerase 2a, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder—a multitissue array study with prognostic implications. Anticancer Res 25(1A):263–271
20. Kolla SB et al (2008) Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40:321–327
21. Kassouf W et al (2008) Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179:353–358
22. Liedberg F et al (2008) Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 26:17–24
23. Bolenz C et al (2010) Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 106:1216–1222
24. Lammers RianneJM, Witjes Alfred (2011) Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853–858
25. Greene FL et al (2002) AJCC cancer staging Manual, 6th edn. Springer, New York, p 2002
26. Chen Z et al (2012) The 1973 WHO classification is more suitable than the 2004 WHO classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS One 7:e47199. doi:10.1371/journal.pone.0047199
27. Schrier BP et al (2004) Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45:292–296
28. Chen PC, Yu HJ, Chang YH, Pan CC (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66:113–119
29. Olsson H, Fyhr IM, Hultman P, Jahnson S (2012) HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol 46:102–107
30. Lae M et al (2010) Assessing HER-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:815–819
31. Denzinger S et al (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53:146–152